Tenofovir DF
INDICATIONS
FDA
FDA
- Treatment of HIV infection in adults and pediatric patients (≥2 years of age, weighing ≥10 kg) in combination with other antiretroviral drugs.
- Treatment of chronic HBV in adults and children ≥2 years of age and weighing ≥10 kg
- HIV pre-exposure prophylaxis (PrEP) for at-risk adults and adolescents weighing ≥35 kg (in combination with emtricitabine as Truvada [FTC/TDF])
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prevention of perinatal HBV transmission in eligible pregnant patients in conjunction with appropriate infant immunoprophylaxis
- HIV post-exposure prophylaxis (PEP)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 2, 2026
Citation
Soto, Caitlin, and Fidelia Bernice. "Tenofovir DF." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540541/all/Tenofovir_DF.
Soto C, Bernice F. Tenofovir DF. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540541/all/Tenofovir_DF. Accessed November 22, 2026.
Soto, C., & Bernice, F. (2026). Tenofovir DF. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540541/all/Tenofovir_DF
Soto C, Bernice F. Tenofovir DF [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 November 22]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540541/all/Tenofovir_DF.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tenofovir DF
ID - 540541
A1 - Soto,Caitlin,PharmD, BCIDP
AU - Bernice,Fidelia,Pharm.D., BCIDP
Y1 - 2026/11/02/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540541/all/Tenofovir_DF
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -

Johns Hopkins ABX Guide

